Core Viewpoint - The beauty industry is increasingly entering the medical aesthetics channel, with over 20 beauty brands adopting a dual beauty strategy of "medical aesthetics + beauty" to enhance their market presence and professional credibility [2][6][30]. Group 1: Market Overview - The medical aesthetics market in China is experiencing strong growth, with 18,584 compliant specialized medical aesthetics institutions reported as of January 2024 [6][7]. - The main active regions for medical aesthetics consumption are concentrated in the Pearl River Delta, Yangtze River Delta, and Chengdu-Chongqing areas [7][8]. Group 2: Industry Structure - Medical aesthetics institutions can be categorized into three types: public hospitals, large chain private hospitals, and small private hospitals and clinics [4][5]. - The development of the domestic medical aesthetics industry has gone through three main stages: initiation (1994-2000), gradual standardization (2000-2010), and rapid development (2010-present) [5]. Group 3: Brand Strategies - Many beauty companies have established significant medical aesthetics channel layouts, such as Huaxi Biological covering 7,000 medical institutions and Juzhi Biological entering approximately 1,700 public hospitals and 3,000 private hospitals and clinics [8][10]. - International beauty brands are also accelerating their medical aesthetics channel expansion, with brands like SkinCeuticals and Estée Lauder entering high-end medical aesthetics lines [10][12]. Group 4: Consumer Trends - There is a growing consumer demand for effective skincare solutions that combine beauty products with medical treatments, reflecting a trend towards the integration of lifestyle beauty and medical aesthetics [17][20]. - Consumers are increasingly seeking products with professional medical backing and comprehensive management solutions from pre-operative care to post-operative recovery [18][20]. Group 5: Challenges and Opportunities - Despite the initial success of some brands in the medical aesthetics channel, challenges remain, including product quality inconsistency and the need for effective consumer education [16][18][20]. - The dual beauty model is becoming a significant trend, with medical aesthetics companies also venturing into lifestyle beauty, leveraging their technical expertise and clinical data [22][23]. Group 6: Future Outlook - The competition in the medical aesthetics channel is expected to intensify, with beauty brands needing to establish unique advantages through solid technical research and deep medical collaboration [29][30]. - The future winners in this space will be those who can embed "professional trust" in the medical aesthetics channel and leverage "real clinical value" to gain endorsements from both doctors and consumers [30].

Core Insights - The "2025 High-Quality Consumer Brand TOP100 Innovation Ecological Conference" will be held in Shanghai, focusing on brand influence, innovation, social responsibility, and company scale [1] - A report titled "2025 High-Quality Consumer Brand TOP100 Trend Insight" will be released, highlighting four major trends in high-quality consumer brands [1] Group 1: Trends in High-Quality Consumer Brands - The rise of health consciousness is driving the growth of wellness and sports consumption, with outdoor sports and health products seeing the highest brand representation [5][6] - AI technology is enhancing product and service upgrades across various sectors, becoming a core competitive advantage in high-end home appliances [5][36] - Novel experiences are igniting consumer enthusiasm, particularly in the experience economy, where immersive and interest-based consumption is gaining traction [6][25] - Emotional value is unlocking new consumption scenarios, especially among younger consumers who prioritize emotional connections in their purchases [6][27] Group 2: Brand Distribution and Characteristics - Nearly 300 brands are competing across nine major sectors, with the largest representation in the beauty economy (23.6%) and health food sector (18.1%) [2][3] - Over 70% of the candidate brands are "post-00s brands," indicating a trend towards newer companies [7][8] - The geographical distribution of brands shows a concentration in major cities like Shanghai, Beijing, and Guangzhou, with Shanghai being favored by foreign brands [11][12][14] Group 3: Consumer Behavior and Market Dynamics - The beauty and personal care market is experiencing a shift towards efficacy-driven products, with a notable increase in consumer awareness regarding product effectiveness [16][18] - The outdoor sports market is becoming increasingly segmented, with traditional apparel brands entering the space to capture the growing demand for specialized outdoor gear [19][20] - The health and wellness industry is projected to reach a total revenue of 9 trillion yuan by 2024, driven by a growing awareness of health among consumers [22][23] Group 4: AI and Technology Integration - AI is reshaping the consumer experience across various sectors, with applications in personalized recommendations, smart home devices, and immersive entertainment experiences [35][38] - A significant majority of surveyed companies (87%) believe that AI technology will bring substantial changes to the consumer sector, with many planning to increase AI integration [40][43] - The integration of AI in consumer products is becoming a key trend, with companies focusing on enhancing user experience through intelligent features [36][37]

Core Viewpoint - The company has announced a differentiated dividend distribution plan, with a cash dividend of RMB 0.11 per share (tax included) for the 2024 fiscal year, approved at the annual shareholders' meeting on June 11, 2025 [1][2]. Dividend Distribution Plan - The total share capital, excluding shares in the company's repurchase account, is 481,678,242 shares, with 3,315,538 shares in the repurchase account, resulting in 478,362,704 shares eligible for the dividend distribution [2]. - The cash dividend distribution will not involve capital reserve conversion to share capital or the issuance of bonus shares [1][2]. - The reference price for the ex-dividend (ex-rights) calculation is determined by the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio) [2]. Tax Implications - For individual shareholders and securities investment funds, dividends are subject to different tax treatments based on the holding period. If held for over one year, dividends are exempt from individual income tax. For holdings of one year or less, tax will be calculated upon the sale of shares [3][4]. - Qualified Foreign Institutional Investors (QFIIs) will have a 10% corporate income tax withheld on dividends, resulting in a net cash dividend of RMB 0.099 per share [4]. - For Hong Kong investors holding shares through the "Shanghai-Hong Kong Stock Connect," a 10% withholding tax will also apply, leading to a net cash dividend of RMB 0.099 per share [4]. Implementation Details - Cash dividends will be distributed through the China Securities Depository and Clearing Corporation Limited Shanghai Branch, with specific arrangements for different types of shareholders [3][5]. - Shareholders who have not completed designated trading will have their dividends held by the clearing company until the trading is completed [3].

中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于华熙生物科技股份有限公司 差异化分红事项之专项法律意见书 的陈述应是完整、真实、准确和有效的，并无隐瞒、虚假或重大遗漏之处；签 署文件的主体均应具有签署文件的权利能力和行为能力，所提供文件中的所有 签字和印章均是真实的；文件材料为副本或复印件的，应与正本或原件是一致 和相符；一切足以影响本法律意见书的事实和文件均应向本所披露，而无任何 隐瞒、遗漏、虚假或误导之处；该等事实和文件于提供给本所之日至本法律意 见书出具之日，未发生任何变更； 3、对出具本法律意见书至关重要而又无法得到独立的证据支持的事实，本 所依赖政府有关部门、公 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-025 华熙生物科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/11 | 2025/7/14 | 2025/7/14 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 11 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的除华熙生物科技 股份有限公司回购专用证券账户外的本公司全体股东。 3. 差异化分红送转方案： （1） 差异化分红送转方案 根据公司 2024 年年度股东大会审议通过的《关于公司 2024 年度利润分配预 由于公司本次进行差异化分红送转，上述公式中现金 ...

Core Viewpoint - The article discusses the rising trend of cosmetic surgery among young people in China, particularly focusing on the motivations and psychological impacts behind their decisions to undergo procedures like double eyelid surgery. It highlights how social media influences perceptions of beauty and self-worth, leading to increased demand for cosmetic enhancements among the younger generation [7][50][54]. Group 1: Market Overview - The Chinese medical beauty market is projected to reach a scale of 350 to 400 billion yuan by 2025, with Generation Z (born after 1995) contributing 62% of the consumption share, averaging an annual expenditure of 28,000 yuan, significantly higher than the "post-80s" generation [7][9]. - The demand for medical beauty services is rapidly increasing, leading to the emergence of companies like Huaxi Biological, Aimeike, and Haohai Biological, which are referred to as the "three swordsmen of medical beauty" due to their high profit margins and market presence [9][29]. Group 2: Changing Attitudes Towards Cosmetic Surgery - There is a noticeable shift in attitudes towards cosmetic surgery, with younger individuals increasingly seeking "light medical beauty" options rather than invasive surgeries. This trend reflects a desire for natural-looking enhancements rather than dramatic changes [27][29]. - The acceptance of cosmetic procedures has evolved, with many young people now viewing them as routine, akin to dental corrections, and not requiring justification for their choices [49][54]. Group 3: Psychological Factors - The article emphasizes that many young individuals experience a form of psychological anxiety regarding their appearance, often exacerbated by social media portrayals of beauty standards. This anxiety can lead to a desire for cosmetic procedures as a means of self-improvement [50][53]. - The narrative illustrates that for some individuals, cosmetic surgery serves as a way to alleviate long-standing self-criticism and to embrace their current selves, rather than a complete transformation [54].

Core Insights - The light medical beauty market in China has surpassed half of the overall medical beauty market, becoming the mainstream beauty method by 2024, with significant contributions from non-invasive and minimally invasive procedures [1][2] Market Overview - Light medical beauty is defined as professional medical beauty projects that fall between surgical procedures and lifestyle beauty, utilizing non-invasive or minimally invasive methods for skin management, contour modification, and anti-aging effects [1] - The rapid growth of the light medical beauty market is attributed to its advantages such as minimal trauma, quick recovery, significant results, and relatively low risks, aligning with modern consumers' dual demands for beauty and quality of life [2] Consumer Trends - The penetration rate of the light medical beauty market is increasing, with 34% of consumers planning to engage in light medical beauty services in the coming year, marking a 36% increase from the previous year [4] - Among the interested consumer group, over one-third are new entrants, injecting fresh growth vitality into the Chinese medical beauty industry [4] Popular Products - Injectable and photothermal products are the main attractions for light medical beauty consumers, with ultrasound-based products (e.g., ultrasound scalpel) rapidly gaining popularity [5] Consumption Behavior - Consumers are increasingly rational in their light medical beauty choices, prioritizing needs-based combinations of projects and products, with over half selecting options based on specific needs [7] - The average planned consumption has increased to 2.4 projects per consumer, reflecting a 14% year-on-year growth [7] Consumer Demographics - The consumer base for light medical beauty exhibits high retention and strong growth, with seasoned consumers making up 35% of the existing market, indicating their essential role in the market [10] - Among the new consumer group, high-end novices represent 38%, characterized by high standards for beauty and a willingness to pay, with a focus on facial anti-aging solutions [10]

Core Insights - The article discusses recent developments in the nutrition and health industry, highlighting regulatory changes, new product approvals, and market trends that could impact investment opportunities [2][3][4][5][6]. Regulatory Developments - The State Administration for Market Regulation issued a guideline clarifying the definition of commercial advertising under the Advertising Law, addressing ongoing disputes in advertising enforcement [2]. - The National Health Commission approved D-alloheptulose and four other substances as new food raw materials, indicating a push for innovation in the nutrition sector [3]. - The market regulator released multiple responses to proposals regarding health food regulations, signaling a focus on traditional Chinese medicine formulations as a potential growth area [4]. Market Trends and Investment Opportunities - Yangtuo Technology Inc. submitted an IPO application to the Hong Kong Stock Exchange, aiming to raise funds for market expansion and supply chain optimization, reflecting growing investor interest in the nutrition and health sector [5]. - A report on 68 nutrition and health companies showed an average market value increase of 20% in the first half of the year, driven by rising consumer health awareness and demand for nutritional products [6]. Company Performance - New Hope Liuhe (002001) projected a net profit of 3.3 billion to 3.75 billion yuan for the first half of 2025, representing a year-on-year growth of 50% to 70% [12]. - Brother Technology (002562) expects a net profit of 60 million to 75 million yuan for the same period, marking an increase of 325% to 431% compared to the previous year [13]. New Product Launches - Guangji Pharmaceutical (000952) received a notice of administrative penalty for information disclosure violations, indicating regulatory scrutiny in the sector [14]. - TCM brand Tongrentang launched its first OTC glucosamine product, expanding its product line in the bone and joint health category [14].

Core Viewpoint - The report outlines a significant reduction in shareholding by Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership) in Jiahe Meikang (Beijing) Technology Co., Ltd., decreasing its stake to 10% due to financial needs and dilution from stock incentives [1][5]. Group 1: Shareholding Changes - The information disclosure obligor reduced its shareholding from 19,569,619 shares (14.19%) to 13,758,560 shares (10.00%) following a series of transactions [7][8]. - The reduction in shareholding was influenced by the company's issuance of restricted stock and stock options, leading to a dilution of the obligor's stake [5][9]. - The total share capital of Jiahe Meikang was adjusted from 137,877,502 shares to 137,585,598 shares as a result of these changes [8][10]. Group 2: Future Plans - The information disclosure obligor plans to reduce its holdings by up to 4,127,566 shares (3.00% of total shares) within the next 12 months through centralized bidding and block trading [5][6]. - As of the report date, the obligor's reduction plan remains incomplete, and future changes in shareholding are uncertain [5][11]. Group 3: Legal Compliance - The report confirms that the information disclosure obligor has complied with relevant laws and regulations, ensuring the accuracy and completeness of the disclosed information [2][12]. - The obligor has not engaged in any other transactions involving the company's shares in the six months prior to the report [10][13].

Core Insights - Japan's beauty medical industry has reached a market size of approximately 594 billion yen, surpassing South Korea to become the new "cosmetic powerhouse" [2] - The growth of Japan's medical beauty market has been significant, with a 120% increase in 2021 and a continued rise in demand for various treatments [3] - Male consumers have become a major driving force in the industry, with the number of male clients increasing 16 times over the past decade [4] Market Growth - The medical beauty market in Japan expanded 2.39 times from 2009 to 2023, indicating a robust growth trajectory [4] - In 2023, the market size reached over 500 billion yen, reflecting a growth of 108.8% compared to the previous year [3] Consumer Behavior - Approximately 70% of surveyed men express concern about their appearance, with 43% considering some form of beauty medical treatment [5] - The pressure of workplace competition and the desire for self-confidence are significant motivators for men seeking cosmetic procedures [5][6] Economic Context - Japan's employment rate for new graduates reached a historic high of 98.1% in 2024, but the country faces a demographic challenge with a declining birth rate and an increasing death rate [5] - The economic downturn has led individuals to invest in their appearance as a strategy to enhance job security and competitiveness [9] Industry Comparison - Japan's medical beauty culture is evolving, with a notable increase in public acceptance and participation in cosmetic procedures [11] - The country aspires to replicate South Korea's successful model of integrating medical beauty with tourism and consumption, although challenges remain [12][13] Regulatory Environment - Japan's medical beauty industry currently lacks stringent regulatory oversight, leading to a rise in complications from procedures performed by non-specialist doctors [19] - The increase in reported complications highlights the need for improved regulatory measures to ensure patient safety [19] Investment Trends - Global beauty companies are increasingly investing in the medical beauty sector, with major brands like L'Oréal and Estée Lauder expanding their offerings [21][22] - Despite the growth potential, there are concerns about the sustainability of the medical beauty market, as evidenced by declining average spending per customer and increased competition [27]